Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Dealing

12 Aug 2014 11:49

RNS Number : 9031O
PuriCore Plc
12 August 2014
 



Director Dealing

 

12 August 2014 - PuriCore plc (LSE: PURI) (the "Company"), a global company focused on safe and effective protection against the spread of infectious pathogens, today announces a director dealing, in accordance with the Disclosure and Transparency Rules. On 11 August 2014, the following Director notified the Company that he had purchased ordinary shares of 10p each in the share capital of the Company ("Shares"), as set out below.

 

 

Name

Date Purchased

Number of Shares Purchased

Purchase Price of Shares

Shareholding following the Acquisition

Percentage of Issued Share Capital

Michael Ashton (CEO)

Michael Ashton (CEO)

11 August 2014

11 August 2014

50,000

100,000

35p

39p

Total Dealing

150,000

169,350

0.34%

 

 

Enquiries:

UK

US

FTI Consulting

Sage Strategic Marketing

Mo Noonan/Simon Conway

Jennifer Guinan

Victoria Foster Mitchell

+1 610.410.8111

+44 203 727 1000

jennifer@sagestrat.com

 

 

About PuriCore

PuriCore plc (LSE: PURI) is a global company focused on safe and effective protection against the spread of infectious pathogens without causing harm to human or animal health or to the environment. PuriCore's antimicrobial technology and complementary products are used in a well-established core business and emerging sectors of two broad markets: Food & Agriculture and Health Sciences. In the Food & Agriculture market, PuriCore's portfolio is used by thousands of US supermarket retailers, including three of the top-five, to provide savings in labour costs and improvements in inventory loss and to address cross contamination of pathogens on fresh produce and floral products. In the Health Sciences market, PuriCore's breakthrough wound care technology is used to treat chronic and acute wounds including diabetic ulcers and burns in humans, for atopic dermatitis as private-labelled dermatologic treatments for humans, and to manage wounds in all species of companion and farm animals in the animal health segment. PuriCore is headquartered in Malvern, Pennsylvania. To receive additional information on PuriCore, visit www.puricore.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSGGUQCRUPCGUP
Date   Source Headline
4th Jun 20144:46 pmRNSPublication of Circular
4th Jun 20147:00 amRNSSale of Endoscopy Business
14th May 20147:00 amRNSInterim Management Statement
24th Apr 20147:00 amRNSFinal Results
10th Apr 20147:00 amRNSNotice of Results
19th Feb 201411:22 amRNSBlocklisting Interim Review
18th Feb 20147:00 amRNSTrading Statement
13th Feb 20147:00 amRNSMiddle East Wound Care Marketing Agreement
7th Nov 20137:00 amRNSRe Agreement
6th Nov 20138:50 amRNSHolding(s) in Company
4th Nov 201310:03 amRNSHolding(s) in Company
1st Nov 20137:00 amRNSDirector/PDMR Shareholding
28th Oct 20137:00 amRNSInterim Management Statement
22nd Oct 20137:00 amRNSLaunches New Animal Health Wound Product NovaZo
15th Oct 20137:00 amRNSDirector Details
11th Oct 20137:00 amRNSReached agreement with Misonix
27th Sep 20137:00 amRNSValue Creation Plan Update
6th Sep 20131:58 pmRNSDirector Dealing
16th Aug 20133:24 pmRNSDirector Dealing
12th Aug 20131:59 pmRNSShare Option Grant
8th Aug 20137:00 amRNSHalf Yearly Report
2nd Aug 20137:00 amRNSBlocklisting Interim Review
17th Jul 20137:00 amRNSNotice of Results
28th Jun 20137:00 amRNSTotal Voting Rights
26th Jun 201311:19 amRNSResult of AGM
20th Jun 20137:00 amRNSPuriCore signs $13.5 million US deal
19th Jun 20131:16 pmRNSAGM Update
11th Jun 20133:08 pmRNSHolding(s) in Company
11th Jun 20133:06 pmRNSHolding(s) in Company
5th Jun 20131:13 pmRNSHolding(s) in Company - Replacement
5th Jun 20131:10 pmRNSHolding(s) in Company - Replacement
4th Jun 20133:04 pmRNSHolding(s) in Company
4th Jun 20133:01 pmRNSHolding(s) in Company
17th May 20137:46 amRNSInterim Management Statement
14th May 20137:00 amRNSBoard Changes
2nd May 20137:00 amRNSShare Option Grant
1st May 20137:00 amRNSTotal Voting Rights
30th Apr 20137:00 amRNSFinal Results
17th Apr 20131:57 pmRNSNotice of Results
8th Apr 20137:00 amRNSPuriCore Signs Major US Deal
3rd Apr 20137:00 amRNSPuriCore Signs Vashe Marketing Agreement
7th Mar 20137:00 amRNSTrading Update
6th Mar 20137:00 amRNSPuriCore Partners with Onset Dermatologics
5th Mar 20137:00 amRNSBoard and Organisational Changes
15th Feb 20135:20 pmRNSBlocklisting Interim Review
14th Feb 20137:00 amRNSFDA 510(k) Clearance
12th Feb 20136:01 pmRNSShare Option Grant and Blocklisting Update
7th Feb 20135:39 pmRNSApplication for Blocklisting
1st Feb 20134:40 pmRNSSecond Price Monitoring Extn
1st Feb 20134:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.